Trevi Therapeutics
-
2011
Company Description
Trevi Therapeutics develops drugs for treating uremic pruritus.
Trevi Therapeutics, Inc. develops drugs for the treatment of uremic pruritus. Its pipeline product, T111 is an oral extended release formulation for the treatment of severe chronic itching condition. The company was founded in 2011 and is based in New Haven, Connecticut.
-
Manufacturer:
Science and Engineering -
Formed:
2011 -
Company Website:
-
Company E-mail:
-
Company Address:
52 Charter Ridge RoadSandy Hook, CTUnited States -
We recognize our sponsors starting at $1 per entry.
Learn more at https://www.ithistory.org/benefits